title: Bankruptcy filing worries developers of nanoparticle cancer drugs.
authors.forename: Heidi
authors.initials: H
authors.lastname: Ledford
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000493:pharmacokinetics; D016361:Bankruptcy / Q000191:economics* / Q000331:legislation & jurisprudence*; D001709:Biotechnology / Q000191:economics* / Q000639:trends; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000191:economics* / Q000639:trends; D006801:Humans; D007449:Investments / Q000191:economics / Q000639:trends; D050997:Nanomedicine / Q000191:economics* / Q000639:trends; D053758:Nanoparticles / Q000008:administration & dosage / Q000191:economics*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D057285:Precision Medicine / Q000379:methods / Q000639:trends; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; C506643:liposomal doxorubicin; D000077143:Docetaxel; D011092:Polyethylene Glycols; D004317:Doxorubicin